Trial
NCT01609582
Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease
Phase IIITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Takeda
Collaborators
—
Condition
Type 2 Diabetes
Intervention
TAK-875
Why stopped
Due to potential concerns about liver safety (See Detailed Description)
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-10-19